Some Lucentis patients have had detached retinas and serious infections inside the eye. If the eye becomes red, sensitive to light, or painful, or if there is a change in vision, patients should call ...

The Genentech Inc. eye drug Lucentis performed well in a late-stage study of patients with diabetic macular edema — a treatment that could be rejected in the United Kingdom — but the real insight ...

ZURICH, May 4 (Reuters) - Swiss drugmaker Novartis AG said on Wednesday a new study showed that its Lucentis eye drug is safer than cancer drug Avastin for treating macular degeneration. Novartis said ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. An FDA advisory panel recommended Thursday that Genentech ...

Switzerland's Novartis and Roche were fined 444 million euros ($522 million) by France, after its competition authority said on Wednesday they used abusive practices to push costly eye injection ...

Pfenex and Hospira, which is in the process of being acquired by Pfizer, are teaming up to develop the former’s biosimilar of Roche and Novartis’ eye blockbuster Lucentis. Pfenex and Hospira, which is ...

Building on this success, the Alberta government says it is launching a new permanent program, the Alberta Retinal Treatment Program, effective Oct. 1. The new program is expected to expand ...